Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Treatment of Patients with Early Breast Cancer: 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Update Breast Cancer 2024 Part 2 – Patients with Early Stage Breast Cancer (2025) Janni W, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification (2025) Galas K, Gleitsmann M, Rey J, Solbach C, Witzel I, Karn T, Schmatloch S, et al. Journal article Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study (2025) Fasching P, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, et al. Journal article Patterns of Associations with Epidemiologic Factors by High-Grade Serous Ovarian Cancer Gene Expression Subtypes (2025) Collin LJ, Cushing-Haugen KL, Terry KL, Goode EL, Wu AH, Harris HR, Sasamoto N, et al. Journal article